Effect of Irbesartan and Losartan on Pharmacokinetics of Cyclosporin A in Rabbits
Liu Xin-hui
Abstract
Liu Xin-hui
Abstract
OBJECTIVE:To study the effect of irbesartan and losartan on pharmacokinetics of cyclosporin A(CsA)in rabbits. METHODS: 12 rabbits were randomly divided into two groups(n=6). In self-controlled study,plasma concentration of CsA in rabbits of two groups before and after treating with combination of irbesartan and losartan were determined and pharmacokinetics parameters were examined. RESULTS: After combination of irbesartan or losartan,the Cmax and AUC0~24 of CsA were significantly increased(P0.01),plasma clearance(CL)and apparent volume of distribution(Vd)significantly decreased(P0.05 or P 0.01). The remaining pharmacokinetic parameters had no significant changes. CONCLUSION: Irbesartan and losartan can increase blood concentrations of CsA and the combination use of the two drugs in clinic requires monitoring CsA blood concentration to ensure safe and effective treatment.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE:To study the effect of irbesartan and losartan on pharmacokinetics of cyclosporin A(CsA)in rabbits. METHODS: 12 rabbits were randomly divided into two groups(n=6). In self-controlled study,plasma concentration of CsA in rabbits of two groups before and after treating with combination of irbesartan and losartan were determined and pharmacokinetics parameters were examined. RESULTS: After combination of irbesartan or losartan,the Cmax and AUC0~24 of CsA were significantly increased(P0.01),plasma clearance(CL)and apparent volume of distribution(Vd)significantly decreased(P0.05 or P 0.01). The remaining pharmacokinetic parameters had no significant changes. CONCLUSION: Irbesartan and losartan can increase blood concentrations of CsA and the combination use of the two drugs in clinic requires monitoring CsA blood concentration to ensure safe and effective treatment.
Key concepts: Irbesartan, Losartan, Pharmacokinetics, Cmax, Pharmacology, Volume of distribution, Medicine, Losartan Potassium